摘要:
The invention relates to a class of CpG immunostimulatory oligonucleotides containing a 5′TCG motif or a CG at or near the 5′ end that are useful for stimulating an immune response.
摘要:
Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5′ TCGTCGTTTTCGGCGCGCGCCGT 3′ (SEQ ID NO: 1), in which each C is unmethylated and 3′ refers to the 3′ end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-γ. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.
摘要翻译:公开了含有CpG免疫刺激基序和能够形成二级结构的第二基序的免疫刺激性寡核苷酸,包括体外和体内的双链体和高级结构。 它们包括具有碱基序列的核酸或其药学上可接受的盐,其包含5'TCGTCGTTTTCGGCGCGCGCCGT 3'(SEQ ID NO:1),其中每个C是未甲基化的,3'是指核酸的3'末端。 寡核苷酸激活B细胞和NK细胞并诱导I型干扰素和干扰素-γ的表达。 寡核苷酸可用于治疗各种疾病和病症,包括过敏,哮喘,感染和癌症。 除了它们作为单一药剂和联合疗法的用途之外,所公开的寡核苷酸可用作疫苗中的佐剂。
摘要:
A class of immunostimulatory nucleic acids having at least two functionally and structurally defined domains is provided. This class of combination motif immunostimulatory nucleic acids activates an immune response and is useful for treating a variety of immune related disorders such as cancer, infectious disease, and allergic disorders. The nucleic acids also stimulate activation of natural killer cells and production of type 1 interferon.
摘要:
The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.
摘要:
The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.
摘要:
Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5′ TCGTCGTTTTCGGCGCGCGCCGT 3′ (SEQ ID NO: 1), in which each C is unmethylated and 3′ refers to the 3′ end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-γ. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.
摘要翻译:公开了含有CpG免疫刺激基序和能够形成二级结构的第二基序的免疫刺激性寡核苷酸,包括体外和体内的双链体和高级结构。 它们包括具有碱基序列的核酸或其药学上可接受的盐,其包含5'TCGTCGTTTTCGGCGCGCGCCGT 3'(SEQ ID NO:1),其中每个C是未甲基化的,3'是指核酸的3'末端。 寡核苷酸激活B细胞和NK细胞并诱导I型干扰素和干扰素-γ的表达。 寡核苷酸可用于治疗各种疾病和病症,包括过敏,哮喘,感染和癌症。 除了它们作为单一药剂和联合疗法的用途之外,所公开的寡核苷酸可用作疫苗中的佐剂。
摘要:
The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e., CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g., at any stage of the cancer).
摘要:
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.